Recruiting
ASPIRING
2024-516188-10-00· Phase 4· University Of Edinburgh· Source
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· Phase 3· Gilead Sciences Inc.· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).
2024-518171-59-00· Phase 4· Canisius Wilhelmina Ziekenhuis· Source
Recruiting
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· Phase 3· Amsterdam UMC Stichting· Source
Recruiting
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
NCT06766461· Phase 4· Erasmus Medical Center· Source
Active, not recruiting
Safe Stop Trial Melanoma
2024-516937-10-01· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source
Active, not recruiting
Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment
2024-517467-23-00· Phase 3· Amsterdam UMC Stichting· Source
Recruiting
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
2024-514055-15-00· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
2023-510312-40-00· Phase 4· Academisch Ziekenhuis Leiden· Source
Recruiting
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
NCT05865743· Phase 3· Radboud University Medical Center· Source
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemic Treatment for early-stage REctal Cancer?
2024-514620-17-00· Phase 2· Radboud universitair medisch centrum Stichting· Source
Recruiting
TAP-TAU
2023-505430-10-00· Phase 2/3· Amsterdam UMC· Source
Active, not recruiting
Safe Stop ipi-nivo
2024-516938-34-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Active, not recruiting
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· Phase 3· AbbVie Deutschland GmbH & Co. KG· Source
Active, not recruiting
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· Phase 4· Rijnstate Hospital· Source
Recruiting
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· Phase 3· Leiden University Medical Center· Source
Recruiting
PROMISE
2023-505626-34-01· Phase 4· University Medical Center Groningen· Source
Recruiting
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study
2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· Phase 3· Daiichi Sankyo· Source
Recruiting
Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation
NCT06168370· Phase 4· St. Antonius Hospital· Source
Active, not recruiting
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
NCT05502250· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Genmab· Source
Active, not recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· Phase 3· University Medical Center Groningen· Source
Recruiting
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· Phase 3· University of Ulm· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
LEGACY
NCT05125276· Phase 4· Amsterdam UMC· Source
Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· Phase 3· Leiden University Medical Center· Source
Active, not recruiting
Induction Chemotherapy for Locally Advanced Rectal Cancer
NCT04838496· Phase 2· Catharina Ziekenhuis Eindhoven· Source
Active, not recruiting
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780· Phase 3· Erasmus Medical Center· Source
Active, not recruiting
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113· Phase 3· The Netherlands Cancer Institute· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Active, not recruiting
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· Phase 3· German CLL Study Group· Source
Recruiting
Induction Chemotherapy for Locally Recurrent Rectal Cancer
NCT04389086· Phase 3· Catharina Ziekenhuis Eindhoven· Source
Active, not recruiting
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
NCT04483739· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
NCT04097470· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Pregnancy Outcomes: Effects of Metformin Study (POEM Study)
NCT02947503· Phase 3· Bethesda Diabetes Research Center· Source
Active, not recruiting
EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
NCT03517137· Phase 2· European Organisation For Research And Treatment Of Cancer· Source
Active, not recruiting
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03673826· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
NCT03463057· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
NCT03620578· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Source
Active, not recruiting
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
NCT03348150· Phase 3· The Netherlands Cancer Institute· Source
Active, not recruiting
Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
NCT02945566· Phase 2/3· University of Birmingham· Source
Recruiting
DRUP trial
NCT02925234· Phase 2· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source
Active, not recruiting
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· Phase 2· The Netherlands Cancer Institute· Source